Liver Pathology Related to Onco-Therapeutic Agents

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Oncotherapeutic agents are crucial for cancer treatment but can lead to diverse liver injuries.
• These injuries range from mild elevations in liver function tests to severe, life-threatening conditions.
• Recent advancements in cancer therapy involve novel drug classes with distinct hepatotoxicity profiles.

Purpose of the Study:

• To review the spectrum of liver injuries associated with newer generation oncotherapeutic agents.
• To discuss the mechanisms and clinical manifestations of drug-induced liver injury (DILI) from these agents.
• To provide insights into the management of hepatotoxicity in patients receiving modern cancer therapies.

Main Methods:

• Comprehensive literature search of peer-reviewed articles on oncotherapeutic agents and liver injury.
• Focus on immune checkpoint inhibitors, protein kinase inhibitors, monoclonal antibodies, and hormonal therapies.
• Inclusion of relevant data on conventional chemotherapy-induced liver damage.

Main Results:

• Newer agents, including immune checkpoint inhibitors and targeted therapies, present unique patterns of liver injury.
• Hepatotoxicity can manifest as autoimmune-like hepatitis, sinusoidal obstruction syndrome, or direct cellular damage.
• Early recognition and intervention are critical for managing severe liver injury.

Conclusions:

• Modern oncotherapeutic agents carry a risk of significant liver injury that requires careful monitoring.
• Understanding the specific hepatotoxic potentials of novel drugs is essential for safe clinical practice.
• Multidisciplinary management involving oncologists and hepatologists can optimize patient outcomes.